CT
TGTX icon

Clearstead Trust’s TG Therapeutics TGTX Stock Holding History

Clearstead Trust’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48
Closed -$1.73K – 1502
2025
Q3 		$1.73K Hold
48
– – ﹤0.01% 1039
2025
Q2 		$1.73K Buy
+48
New +$1.79K ﹤0.01% 996

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Clearstead Trust's TGTX Position: Q4 2025 in Review

Clearstead Trust sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 48 shares — an estimated $1.73K sold.

Clearstead Trust first reported a position in TGTX in Q2 2025 and held it in 2 quarters. The position peaked at $1.73K in Q3 2025. 352 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Clearstead Trust reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Clearstead Trust sold 48 TG Therapeutics shares in Q4 2025, an estimated $1.73K.
  • Clearstead Trust first reported a position in TG Therapeutics in Q2 2025 and held it in 2 quarters.
  • Clearstead Trust's TG Therapeutics position peaked at $1.73K in Q3 2025.
  • 352 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Clearstead Trust's 13F filing for Q4 2025, filed 9 Feb 2026.